Open AccessThis article is
- freely available
Defensins: Potential Effectors in Autoimmune Rheumatic Disorders
Department of Endocrinology, Diabetology and Rheumatology, Heinrich-Heine-University, Moorenstr. 5, 40225 Düsseldorf, Germany
* Author to whom correspondence should be addressed.
Received: 23 June 2011; in revised form: 29 July 2011 / Accepted: 10 August 2011 / Published: 11 August 2011
Abstract: Defensins are small cationic peptides with antimicrobial properties. They constitute a highly conserved innate immune defense mechanism across species. Based on the arrangement of disulfide-bonds, α- and β-defensins are distinguished in humans. Both types of defensin comprise several distinct molecules that are preferentially expressed at epithelial surfaces and in blood cells. In the last decade, multiple immunomodulatory functions of defensins have been recognized, including chemotactic activity, the promotion of antigen presentation, and modulations of proinflammatory cytokine secretion. These findings suggested a role for defensins not only as a first line of defense, but also as connectors of innate and adaptive immune responses. Recently, increasingly accumulating evidence has indicated that defensins may also be involved in the pathogenesis of autoimmune rheumatic disorders such as systemic lupus erythematosus and rheumatoid arthritis. The current review summarizes the data connecting defensins to autoimmunity.
Keywords: defensin; antimicrobial peptide; rheumatology; autoimmune disease
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Vordenbäumen, S.; Schneider, M. Defensins: Potential Effectors in Autoimmune Rheumatic Disorders. Polymers 2011, 3, 1268-1281.
Vordenbäumen S, Schneider M. Defensins: Potential Effectors in Autoimmune Rheumatic Disorders. Polymers. 2011; 3(3):1268-1281.
Vordenbäumen, Stefan; Schneider, Matthias. 2011. "Defensins: Potential Effectors in Autoimmune Rheumatic Disorders." Polymers 3, no. 3: 1268-1281.